中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.037 seconds)

    OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS
    14.
    发明申请
    OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS 有权
    氧自由基作为EDG-1受体激动剂

    公开(公告)号：US20110190490A1

    公开(公告)日：2011-08-04

    申请号：US13003125

    申请日：2009-07-02

    Applicant: Dieter Kadereit ,  Matthias Schaefer ,  Werngard Czechtizky

    Inventor： Dieter Kadereit ,  Matthias Schaefer ,  Werngard Czechtizky

    IPC: C07D413/14 ,  C07D471/04

    CPC classification number: C07D498/04 ,  C07D519/00

    Abstract: The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

    Abstract translation: 本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1，R 2和R 3如权利要求中所定义。 式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于例如治疗动脉粥样硬化，心力衰竭或外周动脉闭塞性疾病等疾病。 本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。

    USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS
    16.
    发明申请
    USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS 审中-公开
    使用尿酸氧化物治疗或预防由异位或再灌注事件引起的心脏疾病或间质性疾病

    公开(公告)号：US20100266567A1

    公开(公告)日：2010-10-21

    申请号：US12715061

    申请日：2010-03-01

    Applicant: Wolfgang LINZ ,  Matthias SCHAEFER

    Inventor： Wolfgang LINZ ,  Matthias SCHAEFER

    IPC: A61K38/44 ,  A61P9/10

    CPC classification number: C12N9/0046 ,  A61K31/375 ,  A61K38/00 ,  C12Y107/03003 ,  A61K2300/00 ,  A61K38/44

    Abstract: The invention relates to the use of a urate oxidase, preferably recombinant urate oxidase, for example rasburicase, for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure.

    Abstract translation: 本发明涉及尿酸氧化酶，优选重组尿酸氧化酶（例如拉帕菌素）用于治疗或预防由缺血性或再灌注事件引起的心脏疾病或间接后遗症，例如在心脏手术期间和之后如CABG（例如， 冠状动脉旁路移植物），PCI（经皮冠状动脉介入治疗），移植，心肌梗死后及用于治疗或预防冠状动脉疾病或心力衰竭，例如充血性心力衰竭。

    Mixing system comprising an extensional flow mixer
    20.
    发明授权
    Mixing system comprising an extensional flow mixer 有权
    包括延伸流动混合器的混合系统

    公开(公告)号：US08876365B2

    公开(公告)日：2014-11-04

    申请号：US13519152

    申请日：2011-01-20

    Applicant: Maria Pollard ,  Steven R. Strand ,  David A. Eversdyk ,  Matthias Schaefer

    Inventor： Maria Pollard ,  Steven R. Strand ,  David A. Eversdyk ,  Matthias Schaefer

    IPC: B01F5/06

    CPC classification number: B01F5/0453 ,  B01F5/0451 ,  B01F5/0456

    Abstract: The invention provides a mixing system comprising the following: A) at least one extensional flow mixer comprising: a generally open and hollow body having a contoured outer surface and having: a single entrance port and a single exit port; a design for compressing a bulk stream, and a design for broadening the bulk stream and the at least one injected additive stream; B) a flow conductor; and C) a primary additive stream injector, as described herein; and wherein the extensional flow mixer is followed by D) a first helical static mixing element that is at least one half “flow conductor diameter (D1)” downstream of the exit port of the extensional flow mixer; and wherein the mixing system comprises at least four helical static mixing elements, placed such that the leading edge of the first helical static mixing element is located perpendicular to the main axis (major axis) of the exit port of the extensional flow mixer.

    Abstract translation: 本发明提供了一种混合系统，其包括以下步骤：A）至少一个延伸流动混合器，其包括：具有轮廓外表面的大体上敞开且中空的主体，具有：单个入口和单个出口; 用于压缩本体流的设计，以及用于扩大本体流和至少一个注入的添加剂流的设计; B）流动导体; 和C）如本文所述的主要添加剂流注入器; 并且其中所述延伸流动混合器之后是D）第一螺旋静态混合元件，其在所述延伸流动混合器的出口的下游具有至少一半“流动导体直径（D1）”）。 并且其中所述混合系统包括至少四个螺旋形静态混合元件，其被布置成使得所述第一螺旋状静态混合元件的前缘位于垂直于所述延伸流动混合器的出口的主轴线（长轴）的位置。

Patent Agency Ranking